PDS Biotechnology Corporation announced it has adopted an amended protocol for its Phase 3 VERSATILE-003 trial of PDS0101 (Versamune HPV) in HPV16-positive recurrent and/or metastatic head and neck cancer. The amendment adds progression-free survival $(PFS)$ as an interim primary endpoint to support a potential accelerated approval pathway, while median overall survival remains the primary endpoint for full approval. The company said it is proceeding with the amended protocol after the FDA’s 30-day review period elapsed without objection. No trial results were reported in the announcement, and no presentation of results was specified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9657887-en) on February 20, 2026, and is solely responsible for the information contained therein.